Intraperitoneal cytokine level in patients with peritoneal surface malignancies. A study of the RENAPE (French Network for Rare Peritoneal Malignancies)

Annals of Surgical Oncology

Volumn 20, Issue 8, 2013, Pages 2655-2662

  Vlaeminck Guillem, Virginie ^a,b,c   Bienvenu, Jacques ^a,b   Isaac, Sylvie ^a,b   Grangier, Blandine ^a   Golfier, François ^a,b,d   Passot, Guillaume ^a,d   Bakrin, Naoual ^a,d   Rodriguez Lafrasse, Claire ^a,b,d   Gilly, François Noël ^a,b,d   Glehen, Olivier ^a,b,d  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b UNIVERSITÉ LYON 1   (France)

^c CENTRE DE GÉNÉTIQUE MOLÉCULAIRE ET CELLULAIRE   (France)

^d UNIVERSITÉ CLAUDE BERNARD LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; SOLUBLE INTERCELLULAR ADHESION MOLECULE 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; APPENDICITIS; ARTICLE; CANCER GRAFT; CANCER PATIENT; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; ENDOMETRIOSIS; FEMALE; HUMAN; INFERTILITY; INTESTINE OBSTRUCTION; LAPAROSCOPIC SURGERY; MAJOR CLINICAL STUDY; MALE; OVARY CYST; PERITONEAL CARCINOMATOSIS INDEX; PERITONEAL FLUID; PERITONEAL FLUID LEVEL; PERITONEAL SARCOMATOSIS; PERITONEUM CANCER; PERITONEUM MESOTHELIOMA; PERITONEUM PSEUDOMYXOMA; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SURGICAL TECHNIQUE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASCITIC FLUID; CARCINOMA; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-10; INTERLEUKIN-6; INTERLEUKIN-8; MALE; MESOTHELIOMA; MIDDLE AGED; PERITONEAL NEOPLASMS; PSEUDOMYXOMA PERITONEI; STATISTICS, NONPARAMETRIC; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84880318004     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-013-2933-6     Document Type: Article

References (37)

1. Sugarbaker PH. Peritoneum as the first-line of defense in carcinomatosis. J Surg Oncol. 2007;95:93-6.
2. Miner TJ, Shia J, Jaques DP, Klimstra DS, Brennan MF, Coit DG. Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy. Ann Surg. 2005;241:300-8.
3. Glehen O, Mohamed F, Gilly FN. Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol. 2004;5:219-28.
4. Sugarbaker PH. Evolution of cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis: are there treatment alternatives? Am J Surg. 2011;201:157-9.
5. Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, et al. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. Cancer. 2010;116:5608-18.
6. Portilla AG, Sugarbaker PH, Chang D. Second-look surgery after cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer: analysis of prognostic features. World J Surg. 1999;23:23-9.
7. Gilly FN, Carry PY, Sayag AC, Brachet A, Panteix G, Salle B, et al. Regional chemotherapy (with mitomycin C) and intra-operative hyperthermia for digestive cancers with peritoneal carcinomatosis. Hepatogastroenterology. 1994;41:124-9.
8. Glehen O, Gilly FN. Quantitative prognostic indicators of peritoneal surface malignancy: carcinomatosis, sarcomatosis, and peritoneal mesothelioma. Surg Oncol Clin N Am. 2003;12:649-71.
9. Ronnett BM, Zahn CM, Kurman RJ, Kass ME, Sugarbaker PH, Shmookler BM. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to "pseudomyxoma peritonei." Am J Surg Pathol. 1995;19:1390-408.
10. Baratti D, Kusamura S, Martinetti A, Seregni E, Laterza B, Oliva DG, et al. Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2007;14:2300-8.
11. Baratti D, Kusamura S, Martinetti A, Seregni E, Oliva DG, Laterza B, et al. Circulating CA125 in patients with peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol. 2007;14:500-8.
12. Baratti D, Kusamura S, Nonaka D, Cabras AD, Laterza B, Deraco M. Pseudomyxoma peritonei: biological features are the dominant prognostic determinants after complete cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg. 2009;249:243-9.
13. Baratti D, Kusamura S, Nonaka D, Langer M, Andreola S, Favaro M, et al. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2008;15:526-34.
14. Deraco M, Nonaka D, Baratti D, Casali P, Rosai J, Younan R, et al. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol. 2006;13:229-37.
15. Mohamed F, Gething S, Haiba M, Brun EA, Sugarbaker PH. Clinically aggressive pseudomyxoma peritonei: a variant of a histologically indolent process. J Surg Oncol. 2004;86:10-5.
16. Mochizuki Y, Nakanishi H, Kodera Y, Ito S, Yamamura Y, Kato T, et al. TNF-alpha promotes progression of peritoneal metastasis as demonstrated using a green fluorescence protein (GFP)-tagged human gastric cancer cell line. Clin Exp Metastasis. 2004;21:39-47.
17. Yonemura Y, Endou Y, Nojima N, Kawamura T, Fujita H, Kaji M, et al. A possible role of cytokines in the formation of peritoneal dissemination. Int J Oncol. 1997;11: 349-58.
18. Ziprin P, Ridgway PF, Pfistermuller KL, Peck DH, Darzi AW. ICAM-1 mediated tumor-mesothelial cell adhesion is modulated by IL-6 and TNF-alpha: a potential mechanism by which surgical trauma increases peritoneal metastases. Cell Commun Adhes. 2003;10:141-54.
19. Sugimoto K, Fujii S, Sago H, Yoshida K, Takemasa T, Yamashita K. Role of marginal stress fibers formed in the rat vascular endothelial cells. Tissue Cell. 1993;25:825-31.
20. Kimura A, Koga S, Kudoh H, Iitsuka Y. Peritoneal mesothelial cell injury factors in rat cancerous ascites. Cancer Res. 1985;45:4330-3.
21. Jacquet P, Sugarbaker P. Influence of wound healing on gastrointestinal cancer recurrence. Wounds. 1995;7:40-7.
22. Jacquet P, Sugarbaker P: Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. In: Sugarbaker P, ed., Peritoneal Carcinomatosis: Principles of Management. Boston, MA: Kluwer Academic Publishers, 1996:359-74.
23. Cheong YC, Shelton JB, Laird SM, Richmond M, Kudesia G, Li TC, et al. IL-1, IL-6 and TNF-alpha concentrations in the peritoneal fluid of women with pelvic adhesions. Hum Reprod. 2002;17:69-75.
24. Skrzypczak J, Szczepanska M, Puk E, Kamieniczna M, Kurpisz M. Peritoneal fluid cytokines and sICAM-1 in minimal endometriosis: search for discriminating factors between infertility and/or endometriosis. Eur J Obstet Gynecol Reprod Biol. 2005;122:95-103.
25. Calhaz-Jorge C, Costa AP, Santos MC, Palma-Carlos ML. Soluble intercellular adhesion molecule 1 in the peritoneal fluid of patients with endometriosis correlates with the extension of peritoneal implants. Eur J Obstet Gynecol Reprod Biol. 2003;106:170-4.
26. Melis M, Pace E, Siena L, et al. Biologically active intercellular adhesion molecule-1 is shed as dimers by a regulated mechanism in the inflamed pleural space. Am J Respir Crit Care Med. 2003;167:1131-8.
27. Mutti L, Piacenza A, Valenti V, Castagneto B, Betta PG. Expression of intercellular adhesion molecule-1 (ICAM-1) by reactive mesothelial cells in pleural effusions. Pathologica. 1993;85:725-8.
28. Nasreen N, Mohammed KA, Hardwick J, Van Horn RD, Sanders KL, Doerschuk CM, et al. Polar production of interleukin-8 by mesothelial cells promotes the transmesothelial migration of neutrophils: role of intercellular adhesion molecule-1. J Infect Dis. 2001;183:1638-45.
29. Yu G, Tang B, Yu PW, Peng ZH, Qian F, Sun G. Systemic and peritoneal inflammatory response after laparoscopic-assisted gastrectomy and the effect of inflammatory cytokines on adhesion of gastric cancer cells to peritoneal mesothelial cells. Surg Endosc. 2010;24:2860-70.
30. Eustace D, Han X, Gooding R, Rowbottom A, Riches P, Heyderman E. Interleukin-6 (IL-6) functions as an autocrine growth factor in cervical carcinomas in vitro. Gynecol Oncol. 1993;50:15-9.
31. Asgeirsson KS, Olafsdottir K, Jonasson JG, Ogmundsdottir HM. The effects of IL-6 on cell adhesion and e-cadherin expression in breast cancer. Cytokine. 1998;10:720-8.
32. Giavazzi R, Nicoletti MI, Chirivi RG, Hemingway I, Bernasconi S, Allavena P, et al. Soluble intercellular adhesion molecule-1 (ICAM-1) is released into the serum and ascites of human ovarian carcinoma patients and in nude mice bearing tumour xenografts. Eur J Cancer. 1994;30A:1865-70.
33. Hayflick JS, Kilgannon P, Gallatin WM. The intercellular adhesion molecule (ICAM) family of proteins. New members and novel functions. Immunol Res. 1998;17:313-27.
34. Vigano P, Pardi R, Magri B, Busacca M, Di Blasio AM, Vignali M. Expression of intercellular adhesion molecule-1 (ICAM-1) on cultured human endometrial stromal cells and its role in the interaction with natural killers. Am J Reprod Immunol. 1994;32:139-45.
35. Gho YS, Kleinman HK, Sosne G. Angiogenic activity of human soluble intercellular adhesion molecule-1. Cancer Res. 1999;59:5128-32.
36. Gho YS, Kim PN, Li HC, Elkin M, Kleinman HK. Stimulation of tumor growth by human soluble intercellular adhesion molecule-1. Cancer Res. 2001;61:4253-7.
37. Becker JC, Dummer R, Hartmann AA, Burg G, Schmidt RE. Shedding of ICAM-1 from human melanoma cell lines induced by IFN-gamma and tumor necrosis factor-alpha. Functional consequences on cell-mediated cytotoxicity. J Immunol. 1991;147:4398-401.